SPDR S&P Pharmaceuticals ETF (XPH)
| Assets | $167.44M |
| Expense Ratio | 0.35% |
| PE Ratio | 13.85 |
| Shares Out | 3.65M |
| Dividend (ttm) | $0.51 |
| Dividend Yield | 1.08% |
| Ex-Dividend Date | Sep 22, 2025 |
| Payout Ratio | 14.92% |
| 1-Year Return | +7.97% |
| Volume | 68,343 |
| Open | 46.24 |
| Previous Close | 45.82 |
| Day's Range | 46.24 - 47.08 |
| 52-Week Low | 35.22 |
| 52-Week High | 48.76 |
| Beta | 0.60 |
| Holdings | 52 |
| Inception Date | Jun 19, 2006 |
About XPH
Fund Home PageThe SPDR S&P Pharmaceuticals ETF (XPH) is an exchange-traded fund that is based on the S&P Pharmaceuticals Select Industry index. The fund tracks an equal-weighted index of US pharmaceutical companies. XPH was launched on Jun 19, 2006 and is issued by State Street.
Top 10 Holdings
27.48% of assets| Name | Symbol | Weight |
|---|---|---|
| Corcept Therapeutics Incorporated | CORT | 3.10% |
| Elanco Animal Health Incorporated | ELAN | 2.77% |
| Crinetics Pharmaceuticals, Inc. | CRNX | 2.75% |
| Supernus Pharmaceuticals, Inc. | SUPN | 2.74% |
| Tarsus Pharmaceuticals, Inc. | TARS | 2.74% |
| Johnson & Johnson | JNJ | 2.71% |
| Jazz Pharmaceuticals plc | JAZZ | 2.70% |
| Ligand Pharmaceuticals Incorporated | LGND | 2.70% |
| Organon & Co. | OGN | 2.65% |
| Harrow, Inc. | HROW | 2.62% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Sep 22, 2025 | $0.10263 | Sep 24, 2025 |
| Jun 23, 2025 | $0.09587 | Jun 25, 2025 |
| Mar 24, 2025 | $0.15332 | Mar 26, 2025 |
| Dec 23, 2024 | $0.15484 | Dec 26, 2024 |
| Sep 23, 2024 | $0.19471 | Sep 25, 2024 |
| Jun 24, 2024 | $0.15573 | Jun 26, 2024 |
News
Drug Tariffs Are a Sideshow. Trump's Next Move Could Hit Pharma Harder.
What unnerves investors is a lack of clarity on drug pricing.
Big Pharma Unfazed by Trump Tariffs, But Small Biotechs Face Vulnerability
Drugmakers have been bracing for levies and sought to get ahead of them with pledges to invest billions more on domestic manufacturing.
Trump announces 100% tariffs on pharmaceutical drugs, beginning October 1
President Donald Trump said Thursday that he will put import taxes of 100% on pharmaceutical drugs, 50% on kitchen cabinets and bathroom vanities, 30% on upholstered furniture and 25% on heavy trucks ...
Pharma stocks gain, as Trump's tariff move actually could be a win for the sector
Pharmaceutical stocks mostly gained Friday, as traders appeared to shrug off or even cheer President Donald Trump's rollout of a new tariff plan for drugmakers.
EU, Japan express confidence in capped US tariffs on drugs
The European Union and Japan expressed confidence on Friday that they had secured limits on U.S. tariffs on pharmaceuticals, which President Donald Trump said he would impose next week at a rate of 10...
India's pharma stock crash after Trump's 100% tariff on branded drugs
India's pharmaceutical stocks were jolted on Friday, when President Donald Trump announced a 100% tariff on imported branded and patented drugs, effective October 1. The move sent shockwaves through g...
Trump announces 100% tariffs on pharmaceuticals unless drug makers are building U.S. factories
President Donald Trump announced a raft of new tariffs late Thursday, including a 100% levy on imported pharmaceuticals unless their manufacturers are actively building factories in the U.S.
Trump announces 100% tariff on imports of branded or patented pharmaceuticals from October 1
The United States will impose a 100% tariff on imports of branded or patented pharmaceutical products from October 1, unless a pharmaceutical company is building a manufacturing plant in the U.S., Pre...
U.S. to impose 100% tariff on branded, patented drugs unless firms build plants locally, Trump says
U.S. to impose 100% tariff on branded, patented drugs unless firms build plants locally, Trump says
Trump hints at higher semiconductor tariffs. Companies could dodge them by doing this.
Trump suggested steep chip-industry tariffs are coming, but there could be breaks for companies that invest in the U.S. Specifics are still sparse.
US FDA announces new program to boost domestic drug manufacturing
The U.S. Food and Drug Administration on Thursday announced a new program to strengthen the domestic pharmaceutical supply chain, by facilitating construction of manufacturing sites in the United Stat...
Trump threatens drugmakers with 250% tariffs. Here's when higher levies could come.
The latest level of tariffs on the pharmaceutical industry is the highest yet from the president.
XPH: Healthcare Dashboard For July
This article provides a top-down view of the healthcare sector based on valuation and quality metrics. Healthcare providers are the most undervalued subsector, while pharma/biotech has the best qualit...
Are Your Health Care ETFs Safe? Trump's New Policies May Trigger Shockwaves Across Pharma Stocks
As the drug industry is in the middle of a growing policy maelstrom in Washington, D.C., investors are closely watching pharmaceutical ETFs to measure market sentiment and ride out the emerging volati...
BMO's Siegerman talks the impact of tariffs on pharmaceutical stocks
Evan Seigerman, BMO, joins 'Fast Money' to talk the impact of tariffs on pharma space.
Trump teases targeted tariffs on overseas drug manufacturers
With the next set of White House–imposed tariffs just hours away from taking effect — including the attention-hogging 104% rate to be levied on products from China as they're imported into the U.S. — ...
Seeking Stocks With Vitality In The Volatile Healthcare Sector
Investors cooled to the healthcare sector in 2024, which dramatically trailed global and US equity markets for the year. any investors are now asking: how will the policy changes under a new US admini...
XPH: A More Balanced Way To Get Exposure To Pharmaceuticals
The SPDR S&P Pharmaceuticals ETF offers broad-based exposure to the U.S. pharmaceuticals sector, making it a good option for investing in the industry. XPH tracks the performance of the S&P Pharmaceut...
XPH: Non-Diversified U.S.-Based Large-Cap Pharma ETF Isn't Very Attractive
XPH's consistent low yield and poor price growth (mostly negative) over both short-run as well as over long-run should be disheartening for investors. Expiration of a large number of patents within 20...
XPH: Revenue Challenges Ahead For U.S. Pharmaceuticals
XPH gives you exposure to a broad-based cut of the US Pharmaceuticals sector. Patent expirations are a major headwind affecting many companies in the industry.
Will 2023 be the year that pharma M&A makes a comeback?
A handful of acquisitions this week point to a more deal-friendly year for biopharma and biotech companies, though none has generated the kind of excitement seen in years past.
XPH: U.S. Pharmaceuticals Stocks Are Probably Fairly Valued, Cyclically Unattractive
XPH invests in U.S. pharmaceuticals stocks. The fund is concentrated in 44 holdings.